17B-estradiol

DRUG3 trials

Sponsors

University of Southern California, Dartmouth-Hitchcock Medical Center, Mary D Chamberlin

Conditions

AtherosclerosisMetastatic Breast Cancer

Phase 1

Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

RecruitingNCT05900895

Mary D ChamberlinMetastatic Breast Cancer

Start: 2024-07-15End: 2028-12-31Target: 6Updated: 2025-11-20

Phase 2

ELITE: Early Versus Late Intervention Trial With Estradiol

CompletedNCT00114517

University of Southern CaliforniaAtherosclerosis

Start: 2004-07-31End: 2013-03-05Updated: 2023-01-18

ER Reactivation Therapy for Breast Cancer

CompletedNCT02188745

Dartmouth-Hitchcock Medical CenterMetastatic Breast Cancer

Start: 2016-03-11End: 2024-07-05Updated: 2024-07-17

Related Papers

Sex steroid hormones and subclinical atherosclerosis progression in postmenopausal women

European Journal of Endocrinology2025-02-214 citations

Abstract PO4-23-08: Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancer

Cancer Research2024-05-02

Subclinical carotid artery atherosclerosis and cognitive function in older adults.

2022-05-0715 citations

Use of oral estradiol plus vaginal progesterone in healthy postmenopausal women.

2021-09-056 citations

Factors Associated With Serum Estradiol Levels Among Postmenopausal Women Using Hormone Therapy

Obstetrics and Gynecology2020-09-0815 citations

Differential Effect of Plasma Estradiol on Subclinical Atherosclerosis Progression in Early vs Late Postmenopause.

2019-02-0123 citations

Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol

New England Journal of Medicine2016-03-30711 citations

Abstract P3-05-03: Estrogen receptor alpha reactivation for the treatment of anti-estrogen-resistant breast cancer

Cancer Research2016-02-15